New study tests secukinumab for back pain patients in korea

NCT ID NCT06905288

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 70 Korean adults with ankylosing spondylitis who have never taken biologic drugs. They will receive secukinumab as part of routine care. Researchers will measure changes in disease activity and inflammation over time to see how effective the treatment is in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: secukinumab
What this could lead to: If successful, this study could confirm that secukinumab is a safe and effective first biologic option for Korean patients with ankylosing spondylitis.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also small (70 participants) and focused on a specific population, so findings may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis rheumatic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Novartis Investigative Site
RECRUITING

Jinju, Gyeongsangnam-do, 52727, South Korea
Novartis Investigative Site
RECRUITING

Busan, 49201, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.